Dimethylarginine Dimethylaminohydrolase 2 Regulates Nitric Oxide Synthesis and Hemodynamics and Determines Outcome in Polymicrobial Sepsis
Author(s) -
Simon Lambden,
Peter D. Kelly,
Blerina AhmetajShala,
Zhen Wang,
Benjamin M. Lee,
Manasi Nandi,
Belén Torondel,
Matthew Delahaye,
Laura Dowsett,
Sophie Piper,
James Tomlinson,
Ben Caplin,
Lucy Colman,
Olga Boruc,
Anna Slaviero,
Lan Zhao,
Eduardo Oliver,
Sanjay Khadayate,
Mervyn Singer,
Francesca Arrigoni,
James Leiper
Publication year - 2015
Publication title -
arteriosclerosis thrombosis and vascular biology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.007
H-Index - 270
eISSN - 1524-4636
pISSN - 1079-5642
DOI - 10.1161/atvbaha.115.305278
Subject(s) - asymmetric dimethylarginine , nitric oxide , knockout mouse , arginine , medicine , nitric oxide synthase , enos , sepsis , in vivo , ex vivo , endocrinology , chemistry , endogeny , pharmacology , biology , biochemistry , amino acid , in vitro , receptor , microbiology and biotechnology
Nitric oxide is a key to numerous physiological and pathophysiological processes. Nitric oxide production is regulated endogenously by 2 methylarginines, asymmetric dimethylarginine (ADMA) and monomethyl-L-arginine. The enzyme that specifically metabolizes asymmetric dimethylarginine and monomethyl-L-arginine is dimethylarginine dimethylaminohydrolase (DDAH). The first isoform dimethylarginine dimethylaminohydrolase 1 has previously been shown to be an important regulator of methylarginines in both health and disease. This study explores for the first time the role of endogenous dimethylarginine dimethylaminohydrolase 2 in regulating cardiovascular physiology and also determines the functional impact of dimethylarginine dimethylaminohydrolase 2 deletion on outcome and immune function in sepsis.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom